Defective interfering particle

Last updated
Predicted secondary structure of the Coronavirus SL-III cis-acting replication element, a genomic structure required for BCoV DI RNA replication RF00496.jpg
Predicted secondary structure of the Coronavirus SL-III cis-acting replication element, a genomic structure required for BCoV DI RNA replication

Defective interfering particles (DIPs), also known as defective interfering viruses, are spontaneously generated virus mutants in which a critical portion of the particle's genome has been lost due to defective replication or non-homologous recombination. [2] [3] The mechanism of their formation is presumed to be as a result of template-switching during replication of the viral genome, although non-replicative mechanisms involving direct ligation of genomic RNA fragments have also been proposed. [4] [5] DIPs are derived from and associated with their parent virus, and particles are classed as DIPs if they are rendered non-infectious due to at least one essential gene of the virus being lost or severely damaged as a result of the defection. [4] A DIP can usually still penetrate host cells, but requires another fully functional virus particle (the 'helper' virus) to co-infect a cell with it, in order to provide the lost factors. [6] [7]

Contents

DIPs were first observed as early as the 1950s by Von Magnus and Schlesinger, both working with influenza viruses. [8] However, direct evidence for DIPs was only found in the 1960s by Hackett who noticed presence of ‘stumpy’ particles of vesicular stomatitis virus in electron micrographs [9] and the formalization of DIPs terminology was in 1970 by Huang and Baltimore. [10] DIPs can occur within nearly every class of both DNA and RNA viruses both in clinical and laboratory settings including poliovirus, SARS coronavirus, measles, alphaviruses, respiratory syncytial virus and influenza virus. [11] [12] [13] [14] [15] [16] [17] [18]

Defection

DIPs are a naturally occurring phenomenon that can be recreated under experimental conditions in the lab and can also be synthesized for experimental use. They are spontaneously produced by error-prone viral replication, something particularly prevalent in RNA viruses over DNA viruses due to the enzyme used (replicase, or RNA-dependent RNA polymerase.) [4] [19] DI genomes typically retain the termini sequences needed for recognition by viral polymerases, and sequences for packaging of their genome into new particles, but little else. [20] [21] The size of the genomic deletion event can vary greatly, with one such example in a DIP derived from rabies virus exhibiting a 6.1 kb deletion. [22] In another example, the size of several DI-DNA plant virus genomes varied from one tenth of the size of the original genome to one half. [23]

Interference

The particles are considered interfering when they affect the function of the parent virus through competitive inhibition [4] during coinfection. In other words, defective and non-defective viruses replicate simultaneously, but when defective particles increase, the amount of replicated non-defective virus is decreased. The extent of interference depends on the type and size of defection in the genome; large deletions of genomic data allow rapid replication of the defective genome. [20] In SARS-CoV-2, synthetic DIPs made by removing 90% of the genome replicate three times faster than the virus. [24] During the coinfection of a host cell, a critical ratio will eventually be reached in which more viral factors are being used to produce the non-infectious DIPs than infectious particles. [20] Defective particles and defective genomes have also been demonstrated to stimulate the host innate immune responses and their presence during a viral infection correlates with the strength of the antiviral response. [11] However, in some viruses such as SARS-CoV-2, the effect of competitive inhibition by interfering particles reduces viral-mediated innate immune responses and inflammation producing a therapeutic effect. [25]

This interfering nature is becoming more and more important for research on virus therapies. [26] [27] It is thought that because of their specificity, DIPs will be targeted to sites of infection. In one example, scientists have used DIPs to create "protecting viruses", which attenuated the pathogenicity of an influenza A infection in mice, through inducing an interferon response, to a point that it was no longer lethal. [28] For SARS-CoV-2, the first synthetic DIPs were made in 2020 [24] and the interference effect was used to generate therapeutic interfering particles (TIPs) that reduced pathogenesis and protected hamsters from serious disease. [29]

Pathogenesis

DIPs have been shown to play a role in pathogenesis of certain viruses. One study demonstrates the relationship between a pathogen and its defective variant, showing how regulation of DI production allowed the virus to attenuate its own infectious replication, decreasing viral load and thus enhance its parasitic efficiency by preventing the host from dying too fast. [30] This also provides the virus with more time to spread and infect new hosts. DIP generation is regulated within viruses: the Coronavirus SL-III cis-acting replication element (shown in the image) is a higher-order genomic structure implicated in the mediation of DIP production in bovine coronavirus, with apparent homologs detected in other coronavirus groups. [1] A more in-depth introduction can be found in Alice Huang and David Baltimore's work from 1970. [10]

Types of defective RNA genomes

  1. Deletions defections are when a fragment of the template is skipped. Examples of this type of defection can be found in tomato spotted wilt virus and Flock House virus. [31] [21]
  2. Snapbacks defections are when replicase transcribes part of one strand then uses this new strand as a template. The result of this can produce a hairpin. Snapback defections have been observed in vesicular stomatitis virus. [32]
  3. Panhandle defections are when the polymerase carries a partially made strand and then switches back to transcribe the 5' end, forming the panhandle shape. Panhandle defections are found in influenza viruses. [33]
  4. Compound defections are when both a deletion and snapback defection happens together.
  5. Mosaic or complex DI genome, in which the various regions may come from the same helper virus genome but in the wrong order; from different helper genome segments, or could include segments of host RNA. Duplications may also occur. [3]

Research

Research has been conducted by virologists to learn more about the interference in infection of host cells and how DI genomes could potentially work as immunostimulatory antiviral agents. [3] Another branch of research has pursued the concept of engineering DIPs into antiviral therapeutic interfering particles (TIPs), [34] a purely theoretical concept until recently. [35] A 2014 article describes the pre-clinical work to test the immunostimulatory effectiveness of a DIP against influenza viruses by inducing the innate antiviral immune responses (i.e., interferon). [36] Subsequent work tested the pre-clinical efficacy of TIPs against HIV [37] and SARS-CoV-2. [24] [25] DI-RNAs have also been found to aid in the infection of fungi via viruses of the family Partitiviridae for the first time, which makes room for more interdisciplinary work. [19]

Several tools as ViReMa [38] and DI-tector [39] have been developed to help to detect defective viral genomes in next-generation sequencing data and high-throughput approaches, such as random-deletion library sequencing (RanDeL-Seq), [40] allow rational mapping of the viral genetic elements that are required for DI-particle propagation.

Related Research Articles

<span class="mw-page-title-main">Antiviral drug</span> Medication used to treat a viral infection

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are a class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees.

Viral evolution is a subfield of evolutionary biology and virology that is specifically concerned with the evolution of viruses. Viruses have short generation times, and many—in particular RNA viruses—have relatively high mutation rates. Although most viral mutations confer no benefit and often even prove deleterious to viruses, the rapid rate of viral mutation combined with natural selection allows viruses to quickly adapt to changes in their host environment. In addition, because viruses typically produce many copies in an infected host, mutated genes can be passed on to many offspring quickly. Although the chance of mutations and evolution can change depending on the type of virus, viruses overall have high chances for mutations.

<span class="mw-page-title-main">Arenavirus</span> Family of RNA viruses

An arenavirus is a bi- or trisegmented ambisense RNA virus that is a member of the family Arenaviridae. These viruses infect rodents and occasionally humans. A class of novel, highly divergent arenaviruses, properly known as reptarenaviruses, have also been discovered which infect snakes to produce inclusion body disease, mostly in boa constrictors. At least eight arenaviruses are known to cause human disease. The diseases derived from arenaviruses range in severity. Aseptic meningitis, a severe human disease that causes inflammation covering the brain and spinal cord, can arise from the lymphocytic choriomeningitis virus. Hemorrhagic fever syndromes, including Lassa fever, are derived from infections such as Guanarito virus, Junin virus, Lassa virus, Lujo virus, Machupo virus, Sabia virus, or Whitewater Arroyo virus. Because of the epidemiological association with rodents, some arenaviruses and bunyaviruses are designated as roboviruses.

Viral pathogenesis is the study of the process and mechanisms by which viruses cause diseases in their target hosts, often at the cellular or molecular level. It is a specialized field of study in virology.

<span class="mw-page-title-main">Viral entry</span> Earliest stage of infection in the viral life cycle

Viral entry is the earliest stage of infection in the viral life cycle, as the virus comes into contact with the host cell and introduces viral material into the cell. The major steps involved in viral entry are shown below. Despite the variation among viruses, there are several shared generalities concerning viral entry.

<span class="mw-page-title-main">Coronavirus packaging signal</span> Regulartory element in coronaviruses

The Coronavirus packaging signal is a conserved cis-regulatory element found in Betacoronavirus. It has an important role in regulating the packaging of the viral genome into the capsid. As part of the viral life cycle, within the infected cell, the viral genome becomes associated with viral proteins and assembles into new infective progeny viruses. This process is called packaging and is vital for viral replication.

<span class="mw-page-title-main">Hepatitis A virus internal ribosome entry site (IRES)</span>

This family represents the internal ribosome entry site (IRES) of the hepatitis A virus. HAV IRES is a 450 nucleotide long sequence located in the 735 nt long 5’ UTR of Hepatitis A viral RNA genome. IRES elements allow cap and end-independent translation of mRNA in the host cell. The IRES achieves this by mediating the internal initiation of translation by recruiting a ribosomal 40S pre-initiation complex directly to the initiation codon and eliminates the requirement for eukaryotic initiation factor, eIF4F.

<span class="mw-page-title-main">Infectious bronchitis virus D-RNA</span>

The Infectious bronchitis virus D-RNA is an RNA element known as defective RNA or D-RNA. This element is thought to be essential for viral replication and efficient packaging of avian infectious bronchitis virus (IBV) particles.

<span class="mw-page-title-main">Tombusvirus 5′ UTR</span>

Tombusvirus 5′ UTR is an important cis-regulatory region of the Tombus virus genome.

<span class="mw-page-title-main">Tombus virus defective interfering (DI) RNA region 3</span>

Tombus virus defective interfering (DI) RNA region 3 is an important cis-regulatory region identified in the 3' UTR of Tombusvirus defective interfering particles (DI).

<span class="mw-page-title-main">Viral shedding</span> Dissemination of mature virions from host cell

Viral shedding is the expulsion and release of virus progeny following successful reproduction during a host cell infection. Once replication has been completed and the host cell is exhausted of all resources in making viral progeny, the viruses may begin to leave the cell by several methods.

<span class="mw-page-title-main">Virus</span> Infectious agent that replicates in cells

A virus is a submicroscopic infectious agent that replicates only inside the living cells of an organism. Viruses infect all life forms, from animals and plants to microorganisms, including bacteria and archaea. Viruses are found in almost every ecosystem on Earth and are the most numerous type of biological entity. Since Dmitri Ivanovsky's 1892 article describing a non-bacterial pathogen infecting tobacco plants and the discovery of the tobacco mosaic virus by Martinus Beijerinck in 1898, more than 11,000 of the millions of virus species have been described in detail. The study of viruses is known as virology, a subspeciality of microbiology.

<span class="mw-page-title-main">Hepatitis C virus nonstructural protein 5A</span>

Nonstructural protein 5A (NS5A) is a zinc-binding and proline-rich hydrophilic phosphoprotein that plays a key role in Hepatitis C virus RNA replication. It appears to be a dimeric form without trans-membrane helices.

Adolfo García-Sastre,(born in Burgos, 10 October 1964) is a Spanish professor of Medicine and Microbiology and co-director of the Global Health & Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in New York City. His research into the biology of influenza viruses has been at the forefront of medical advances in epidemiology.

<span class="mw-page-title-main">Reverse genetics</span> Method in molecular genetics

Reverse genetics is a method in molecular genetics that is used to help understand the function(s) of a gene by analysing the phenotypic effects caused by genetically engineering specific nucleic acid sequences within the gene. The process proceeds in the opposite direction to forward genetic screens of classical genetics. While forward genetics seeks to find the genetic basis of a phenotype or trait, reverse genetics seeks to find what phenotypes are controlled by particular genetic sequences.

<span class="mw-page-title-main">Positive-strand RNA virus</span> Class of viruses in the Baltimore classification

Positive-strand RNA viruses are a group of related viruses that have positive-sense, single-stranded genomes made of ribonucleic acid. The positive-sense genome can act as messenger RNA (mRNA) and can be directly translated into viral proteins by the host cell's ribosomes. Positive-strand RNA viruses encode an RNA-dependent RNA polymerase (RdRp) which is used during replication of the genome to synthesize a negative-sense antigenome that is then used as a template to create a new positive-sense viral genome.

Flock House virus (FHV) is in the Alphanodavirus genus of the Nodaviridae family of viruses. Flock House virus was isolated from a grass grub at the Flock House research station in Bulls, New Zealand. FHV is an extensively studied virus and is considered a model system for the study of other non-enveloped RNA viruses owing to its small size and genetic tractability, particularly to study the role of the transiently exposed hydrophobic gamma peptide and the metastability of the viral capsid. FHV can be engineered in insect cell culture allowing for the tailored production of native or mutant authentic virions or virus-like-particles. FHV is a platform for nanotechnology and nanomedicine, for example, for epitope display and vaccine development. Viral entry into host cells occurs via receptor-mediated endocytosis. Receptor binding initiates a sequence of events during which the virus exploits the host environment in order to deliver the viral cargo in to the host cytosol. Receptor binding prompts the meta-stability of the capsid–proteins, the coordinated rearrangements of which are crucial for subsequent steps in the infection pathway. In addition, the transient exposure of a covalently-independent hydrophobic γ-peptide is responsible for breaching cellular membranes and is thus essential for the viral entry of FHV into host cells.

HSV epigenetics is the epigenetic modification of herpes simplex virus (HSV) genetic code.

ORF7b is a gene found in coronaviruses of the genus Betacoronavirus, which expresses the accessory protein Betacoronavirus NS7b protein. It is a short, highly hydrophobic transmembrane protein of unknown function.

A therapeutic interfering particle is an antiviral preparation that reduces the replication rate and pathogenesis of a particular viral infectious disease. A therapeutic interfering particle is typically a biological agent (i.e., nucleic acid) engineered from portions of the viral genome being targeted. Similar to Defective Interfering Particles (DIPs), the agent competes with the pathogen within an infected cell for critical viral replication resources, reducing the viral replication rate and resulting in reduced pathogenesis. But, in contrast to DIPs, TIPs are engineered to have an in vivo basic reproductive ratio (R0) that is greater than 1 (R0>1). The term "TIP" was first introduced in 2011 based on models of its mechanism-of-action from 2003. Given their unique R0>1 mechanism of action, TIPs exhibit high barriers to the evolution of antiviral resistance and are predicted to be resistance proof. Intervention with therapeutic interfering particles can be prophylactic (to prevent or ameliorate the effects of a future infection), or a single-administration therapeutic (to fight a disease that has already occurred, such as HIV or COVID-19). Synthetic DIPs that rely on stimulating innate antiviral immune responses (i.e., interferon) were proposed for influenza in 2008 and shown to protect mice to differing extents but are technically distinct from TIPs due to their alternate molecular mechanism of action which has not been predicted to have a similarly high barrier to resistance. Subsequent work tested the pre-clinical efficacy of TIPs against HIV, a synthetic DIP for SARS-CoV-2 (in vitro), and a TIP for SARS-CoV-2 (in vivo).

References

  1. 1 2 Raman S, Bouma P, Williams GD, Brian DA (June 2003). "Stem-loop III in the 5' untranslated region is a cis-acting element in bovine coronavirus defective interfering RNA replication". Journal of Virology. 77 (12): 6720–6730. doi:10.1128/JVI.77.12.6720-6730.2003. PMC   156170 . PMID   12767992.
  2. ↑ White KA, Morris TJ (January 1994). "Nonhomologous RNA recombination in tombusviruses: generation and evolution of defective interfering RNAs by stepwise deletions". Journal of Virology. 68 (1): 14–24. doi:10.1128/JVI.68.1.14-24.1994. PMC   236259 . PMID   8254723.
  3. 1 2 3 Marriott AC, Dimmock NJ (January 2010). "Defective interfering viruses and their potential as antiviral agents". Reviews in Medical Virology. 20 (1): 51–62. doi:10.1002/rmv.641. PMID   20041441. S2CID   26359078.
  4. 1 2 3 4 Pathak KB, Nagy PD (December 2009). "Defective Interfering RNAs: Foes of Viruses and Friends of Virologists". Viruses. 1 (3): 895–919. doi: 10.3390/v1030895 . PMC   3185524 . PMID   21994575.
  5. ↑ Gmyl AP, Belousov EV, Maslova SV, Khitrina EV, Chetverin AB, Agol VI (November 1999). "Nonreplicative RNA recombination in poliovirus". Journal of Virology. 73 (11): 8958–8965. doi:10.1128/JVI.73.11.8958-8965.1999. PMC   112927 . PMID   10516001.
  6. ↑ Makino S, Shieh CK, Soe LH, Baker SC, Lai MM (October 1988). "Primary structure and translation of a defective interfering RNA of murine coronavirus". Virology. 166 (2): 550–560. doi:10.1016/0042-6822(88)90526-0. PMC   7131284 . PMID   2845661.
  7. ↑ Palmer SR, Soulsby L, Torgerson P, Brown DW, eds. (2011). Oxford Textbook of Zoonoses: Biology, Clinical Practice, and Public Health Control. OUP Oxford. pp. 399–400. doi:10.1093/med/9780198570028.001.0001. ISBN   978-0-19-857002-8.
  8. ↑ Gard S, Von Magnus P, Svedmyr A, Birch-Andersen A (October 1952). "Studies on the sedimentation of influenza virus". Archiv für die Gesamte Virusforschung. 4 (5): 591–611. doi:10.1007/BF01242026. PMID   14953289. S2CID   21838623.
  9. ↑ Hackett AJ (September 1964). "A possible morphologic basis for the autointerference phenomenon in vesicular stomatitis virus". Virology. 24 (1): 51–59. doi:10.1016/0042-6822(64)90147-3. PMID   14208902.
  10. 1 2 Huang AS, Baltimore D (April 1970). "Defective viral particles and viral disease processes". Nature. 226 (5243): 325–327. Bibcode:1970Natur.226..325H. doi:10.1038/226325a0. PMID   5439728. S2CID   4184206.
  11. 1 2 Sun Y, Jain D, Koziol-White CJ, Genoyer E, Gilbert M, Tapia K, et al. (September 2015). "Immunostimulatory Defective Viral Genomes from Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in Mice and Humans". PLOS Pathogens. 11 (9): e1005122. doi: 10.1371/journal.ppat.1005122 . PMC   4559413 . PMID   26336095.
  12. ↑ Dimmock NJ, Dove BK, Scott PD, Meng B, Taylor I, Cheung L, et al. (2012). "Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established". PLOS ONE. 7 (12): e49394. Bibcode:2012PLoSO...749394D. doi: 10.1371/journal.pone.0049394 . PMC   3521014 . PMID   23251341.
  13. ↑ Saira K, Lin X, DePasse JV, Halpin R, Twaddle A, Stockwell T, et al. (July 2013). "Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus". Journal of Virology. 87 (14): 8064–8074. doi:10.1128/JVI.00240-13. PMC   3700204 . PMID   23678180.
  14. ↑ Petterson E, Guo TC, Evensen Ø, Mikalsen AB (November 2016). "Experimental piscine alphavirus RNA recombination in vivo yields both viable virus and defective viral RNA". Scientific Reports. 6: 36317. Bibcode:2016NatSR...636317P. doi:10.1038/srep36317. PMC   5090867 . PMID   27805034.
  15. ↑ Cattaneo R, Schmid A, Eschle D, Baczko K, ter Meulen V, Billeter MA (October 1988). "Biased hypermutation and other genetic changes in defective measles viruses in human brain infections". Cell. 55 (2): 255–265. doi:10.1016/0092-8674(88)90048-7. PMC   7126660 . PMID   3167982.
  16. ↑ Makino S, Yokomori K, Lai MM (December 1990). "Analysis of efficiently packaged defective interfering RNAs of murine coronavirus: localization of a possible RNA-packaging signal". Journal of Virology. 64 (12): 6045–6053. doi:10.1128/JVI.64.12.6045-6053.1990. PMC   248778 . PMID   2243386.
  17. ↑ Lundquist RE, Sullivan M, Maizel JV (November 1979). "Characterization of a new isolate of poliovirus defective interfering particles". Cell. 18 (3): 759–769. doi:10.1016/0092-8674(79)90129-6. PMID   229964. S2CID   35964939.
  18. ↑ Stauffer Thompson KA, Rempala GA, Yin J (April 2009). "Multiple-hit inhibition of infection by defective interfering particles". The Journal of General Virology. 90 (Pt 4): 888–899. doi:10.1099/vir.0.005249-0. PMC   2889439 . PMID   19264636.
  19. 1 2 Chiba S, Lin YH, Kondo H, Kanematsu S, Suzuki N (February 2013). "Effects of defective interfering RNA on symptom induction by, and replication of, a novel partitivirus from a phytopathogenic fungus, Rosellinia necatrix". Journal of Virology. 87 (4): 2330–2341. doi:10.1128/JVI.02835-12. PMC   3571465 . PMID   23236074.
  20. 1 2 3 Dimmock NJ, Easton AJ, Leppard KN, eds. (2015). "Innate and intrinsic immunity". Introduction to Modern Virology. John Wiley & Sons. pp. 201–217. ISBN   978-1-119-09453-1.
  21. 1 2 Resende R, de Haan P, van de Vossen E, de Avila AC, Goldbach R, Peters D (October 1992). "Defective interfering L RNA segments of tomato spotted wilt virus retain both virus genome termini and have extensive internal deletions". The Journal of General Virology. 73 (10): 2509–2516. doi: 10.1099/0022-1317-73-10-2509 . PMID   1402797.
  22. ↑ Conzelmann KK, Cox JH, Thiel HJ (October 1991). "An L (polymerase)-deficient rabies virus defective interfering particle RNA is replicated and transcribed by heterologous helper virus L proteins". Virology. 184 (2): 655–663. doi:10.1016/0042-6822(91)90435-e. PMID   1887588.
  23. ↑ Patil BL, Dasgupta I (2006). "Defective Interfering Dnas of Plant Viruses". Critical Reviews in Plant Sciences. 25 (1): 47–64. Bibcode:2006CRvPS..25...47P. doi:10.1080/07352680500391295. S2CID   85790514.
  24. 1 2 3 Yao S, Narayanan A, Majowicz S, Jose J, Archetti M (2020-11-23). "A Synthetic Defective Interfering SARS-CoV-2": 2020.11.22.393587. doi:10.1101/2020.11.22.393587.{{cite journal}}: Cite journal requires |journal= (help)
  25. 1 2 Chaturvedi S, Vasen G, Pablo M, Chen X, Beutler N, Kumar A, et al. (December 2021). "Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance". Cell. 184 (25): 6022–6036.e18. doi:10.1016/j.cell.2021.11.004. PMC   8577993 . PMID   34838159.
  26. ↑ Weinberger LS, Schaffer DV, Arkin AP (September 2003). "Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection". Journal of Virology. 77 (18): 10028–10036. doi:10.1128/jvi.77.18.10028-10036.2003. PMC   224590 . PMID   12941913.
  27. ↑ Thompson KA, Yin J (September 2010). "Population dynamics of an RNA virus and its defective interfering particles in passage cultures". Virology Journal. 7: 257. doi: 10.1186/1743-422X-7-257 . PMC   2955718 . PMID   20920247.
  28. ↑ Easton AJ, Scott PD, Edworthy NL, Meng B, Marriott AC, Dimmock NJ (March 2011). "A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo" (PDF). Vaccine. 29 (15): 2777–2784. doi:10.1016/j.vaccine.2011.01.102. PMID   21320545.
  29. ↑ Villanueva MT (December 2021). "Interfering viral-like particles inhibit SARS-CoV-2 replication". Nature Reviews. Drug Discovery. 21 (1): d41573–021–00205-5. doi:10.1038/d41573-021-00205-5. PMID   34873320. S2CID   244935707.
  30. ↑ Lukhovitskaya NI, Thaduri S, Garushyants SK, Torrance L, Savenkov EI (June 2013). "Deciphering the mechanism of defective interfering RNA (DI RNA) biogenesis reveals that a viral protein and the DI RNA act antagonistically in virus infection". Journal of Virology. 87 (11): 6091–6103. doi:10.1128/JVI.03322-12. PMC   3648117 . PMID   23514891.
  31. ↑ Jaworski E, Routh A (May 2017). "Parallel ClickSeq and Nanopore sequencing elucidates the rapid evolution of defective-interfering RNAs in Flock House virus". PLOS Pathogens. 13 (5): e1006365. doi: 10.1371/journal.ppat.1006365 . PMC   5435362 . PMID   28475646.
  32. ↑ Schubert M, Lazzarini RA (February 1981). "Structure and origin of a snapback defective interfering particle RNA of vesicular stomatitis virus". Journal of Virology. 37 (2): 661–672. doi:10.1128/JVI.37.2.661-672.1981. PMC   171054 . PMID   6261012.
  33. ↑ Fodor E, Pritlove DC, Brownlee GG (June 1994). "The influenza virus panhandle is involved in the initiation of transcription". Journal of Virology. 68 (6): 4092–4096. doi:10.1128/JVI.68.6.4092-4096.1994. PMC   236924 . PMID   8189550.
  34. ↑ Metzger VT, Lloyd-Smith JO, Weinberger LS (March 2011). "Autonomous targeting of infectious superspreaders using engineered transmissible therapies". PLOS Computational Biology. 7 (3): e1002015. Bibcode:2011PLSCB...7E2015M. doi: 10.1371/journal.pcbi.1002015 . PMC   3060167 . PMID   21483468.
  35. ↑ Gladstone Institutes. "A New Class of Antiviral Therapy Could Treat COVID-19". www.prnewswire.com (Press release). Retrieved 2021-12-28.
  36. ↑ Dimmock NJ, Easton AJ (May 2014). "Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?". Journal of Virology. 88 (10): 5217–5227. doi:10.1128/JVI.03193-13. PMC   4019098 . PMID   24574404.
  37. ↑ Tanner EJ, Jung SY, Glazier J, Thompson C, Zhou Y, Martin B, Son HI, Riley JL, Weinberger LS (2019-10-30). "Discovery and Engineering of a Therapeutic Interfering Particle (TIP): a combination self-renewing antiviral" (PDF). doi:10.1101/820456. S2CID   208600143.{{cite journal}}: Cite journal requires |journal= (help)
  38. ↑ Routh A, Johnson JE (January 2014). "Discovery of functional genomic motifs in viruses with ViReMa-a Virus Recombination Mapper-for analysis of next-generation sequencing data". Nucleic Acids Research. 42 (2): e11. doi:10.1093/nar/gkt916. PMC   3902915 . PMID   24137010.
  39. ↑ Beauclair G, Mura M, Combredet C, Tangy F, Jouvenet N, Komarova AV (October 2018). "DI-tector: defective interfering viral genomes' detector for next-generation sequencing data". RNA. 24 (10): 1285–1296. doi:10.1261/rna.066910.118. PMC   6140465 . PMID   30012569.
  40. ↑ Notton T, Glazier JJ, Saykally VR, Thompson CE, Weinberger LS (January 2021). "RanDeL-Seq: a High-Throughput Method to Map Viral cis- and trans-Acting Elements". mBio. 12 (1): e01724–20. doi:10.1128/mBio.01724-20. PMC   7845639 . PMID   33468683.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.